Principles of Management of ADHD include psychotherapy and pharmacological threatment.
Behavioural Therapy
Behavioural Therapy
Behavioural Therapy is the only psychotherapy intervention
viable for management of ADHD patients. They serve to alter the social and
physical environment to modify ADHD patient’s behaviour. Models of behavioural
therapy include:
A. Parent Behaviour Training
Parents are trained to implement specific techniques based
on behavioural principles when interacting with child. Parent training sessions
are given weekly and usually include homework sessions to give parents the
opportunity to learn reward systems and strategies for providing consequences
to shape behaviour.
Topics for learning include:
1. Overview of ADHD, social learning theory and
behaviour management principles.
2. Establish daily report cards and checklist for
rewarding bahaviour
3. Attend to appropriate behaviour and ignoring
minor, inappropriate behaviour
4. Effective reprimands and commands
5. Establish and enforcing rules
6. Time-out procedures
7. Incorporating reward and response cost with home
point system
8. Enforcing contingencies and planning ahead for misbehaviour
outside home setting
9. Problem-solving techniques
10. Generalisation and maintenance of program
post-therapy
B. Psychosocial Therapy
Psychosocial Therapy allows trained therapist to speak with
child and family members about handling behviours and emotions to improve social
skills.
C. School-based Programs
Special education services are offered in school settings to
create and individualized education program (IEP) to increase school success
Pharmacological Modality in Treatment of ADHD
Stimulants and non-stimulants can be given and has shown
success in reducing the symptoms of ADHD.
Alternative treatments such as nutrition and exercises could
improve ADHD conditions, however there has been lacking of evidence to suggest
a direct benefit (Larzelere et al 2010)
Stimulants
Methylphenidate Formulations – Concert, Quillivant XR
Methylphenidate HCl blocks reuptake of norepinephrine and dopamine
in presynaptic neuron to increase their availability into extraneuronal space.
It is available in IR, SR, LA, XR, OROS and MTS form.
The common side effects include insomnia, decreased
appetite, weight loss, depression, anxiety, increased blood pressure and pulse
rate, skin irritation
Extended release liquid formulation has been approved by
FDA. Liquid XR could avoid the medication compliance challenges of solid form.
The onset of treatment is 45 minutes and duration of action is 12 hours. It is
also safe and well tolerable and adverse effects were consistent with known
effects of methylphenidate.
Amphetamine Formulations – Dextroamphetamine sulphate, Vyvanse
(prodrug)
LDX (Vyvanse) is a prodrug stimulant approved for management
of ADHD symptoms. LDX is hydrolysed by endogenous enzymes into L-lysine and
D-amphetamine. Swanson et al noted LDX was effective in reducing ADHD symptoms
compared to placebo.
Efficacy was demonstrated between 2-12 hours post-dose. It
is also well tolerable and safe for usage.
Common side effects include insomnia, decreased appetite,
weight loss, depression, anxiety, increased blood pressure and pulse rate. It
is also known to inhibit MAO and CYP2D6. Drug elimination is influenced by
urinary pH and flow rates.
Non-Stimulants
Selective Norepinephrine Reuptake Inhibitor – Atomoxetine (Strattera)
Atomoxetine could increase concentration of NE and dopamine
by acting on presynaptic norepinephrine
transporter in prefrontal cortex
Common side effects include GI upset, nausea, sedation, insomnia, agitation. CYP2D6 inhibitors may increase atomoxetine SS concentrations.
Α2-Adrenergic Agonist - Clonidine (Kapvay), Guanfancine
Clonidine and Guanfacine are also non-stimulant treatments
of ADHD. The extended release forms are approved by FDA for ADHD.
Side effects are low blood pressure (hypotension), low heart rate (bradycardia), constipation, dry mouth, increased appetitie, hypersomnolence, sedation. Guanfancine is less sedating than clonidine as it is thought that the side effect of guanfancine diminishes over
time (Faraone et al 2010). Care should be taken for guanfacine not to be taken
with fatty meals as it may cause increase in exposure.
If withdrawal is indicated, gradual dose reductions are
recommended to reduce withdrawal symptoms such as rebound hypertension and
lightheadedness.
Monitoring Side Effects of Treatment
1. Inquiry by open-ended questions, spontaneous
patient reporting. Structured interview is also possible but there are weakness
in terms of biasness.
2. Commonly observed side effects include appetite
suppression, headache, insomnia, irritability, abdominal pain
3. ECG prior to treatment initiation + regular
blood pressure and auscultation examintion as there are risk of sudden cardiac
death secondary to cardiac abnormalities and cardiovascular effects of drugs.
Thorough family history of cardiac events should also be taken.
4. Consider drug holidays or dose alteration if
there are significant side effects.